Selskabets formål er at drive handel og industri.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 26.4 mio. | 514 t. | 53.9 mio. | 37.5 mio. | 2 | |
CVR: 17981994
Secondary names: Norpharma A/S
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Mundipharma A/S is experiencing a declining trend in revenue and profitability, with a significant drop from 51.6 million DKK in 2020 to 26.4 million DKK in 2024. Profit has also decreased, falling from 909,958 DKK in 2021 to just 514,000 DKK in 2024. Despite a stable equity position of 37.5 million DKK in 2024, the declining margins raise concerns about the company's operational efficiency and market competitiveness. Positioned within the pharmaceutical wholesale industry, Mundipharma A/S may need to reassess its strategies to reverse this downward trajectory.
AI-generated summary
Companies in the same industry and area
CVR 34362440
CVR 37642185
CVR 44558254
CVR 59238213
CVR 32122337
Elliot James Haddock joined the board
Sarah Anna Heidrich left the board
companydata.dk